We report the cardioprotective effects of moderate aerobic exercise from parallel pediatric murine models of doxorubicin (Doxo) exposure in non-tumor-bearing immune competent (NTB-IC) mice and tumor-bearing nude mice (TB-NM). In both models, animals at 4 weeks of age underwent Doxo treatment with or without 2 weeks of simultaneous exercise. In sedentary NTB-IC or TB-NM mice, Doxo treatment resulted in a statistically significant decrease in ejection fraction and fractional shortening compared with control animals. Interestingly, moderate aerobic exercise during Doxo treatment significantly mitigated decreases in ejection fraction and fractional shortening. In contrast, these protective effects of exercise were not observed when exercise was started after completion of Doxo treatments. Moreover, in the TB-NM model, Doxo caused a decrease in heart mass: tibia length and in body weight that was prevented by exercise, whereas NTB-IC mice exhibited no change in these measurements. Doxo delivery to the hearts of TB-NM was decreased by consistent moderate aerobic exercise before Doxo injection. These findings demonstrate the important but subtle differences in cardiotoxicity observed in different mouse models. Collectively, these results also strongly suggest that aerobic exercise during early-life Doxo exposure mitigates cardiotoxicity, possibly through altered delivery of Doxo to myocardial tissue.
A nthracycline chemotherapies, such as doxorubicin (Doxo), are among the most effective anticancer agents utilized in regimens for over half of all childhood cancer patients. 1 Unfortunately, exposure to Doxo during childhood is unequivocally linked to increased rates of cardiac disease decades later. [1] [2] [3] [4] [5] [6] [7] Recent epidemiologic studies indicate that the cumulative incidence of heart failure in long-term pediatric cancer survivors may be as high as 20% by age 50. 8 Because the number of childhood cancer survivors in the United States is expected to surpass half a million by 2020, 9 it is imperative that novel strategies to mitigate anthracycline-induced cardiac damage are evaluated in relevant preclinical models, as a precursor to logically designed clinical trials.
A widely accepted mechanism by which Doxo induces damage to cell populations that comprise myocardium is through the production of reactive oxygen species that damage mitochondria and induce apoptosis. 1, [10] [11] [12] [13] There are a variety of potential therapeutic strategies that could be beneficial in reducing the amount of reactive oxygen species produced in heart tissue when Doxo accumulates. Among these strategies is aerobic exercise, which is known to decrease oxidative stress in myocytes and other cells in the heart. 14, 15 Importantly, reduction of oxidative stress and cardioprotection by aerobic exercise has already been validated in various preclinical models of cardiac injury including myocardial infarction, ischemia reperfusion, and heart failure. 16 With respect to Doxo-induced cardiotoxicity, aerobic exercise has been previously shown to mitigate cardiac dysfunction in adult rat and mouse models. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] However, these studies do not adequately reflect the clinical scenario in pediatric oncology, where patients are exposed to Doxo early in life when the heart is actively growing and still undergoing development. The vast majority of prior animal studies have all focused on the effects of exercise in Doxotreated adult animals and the protective effects of exercise on Doxo-induced cardiotoxicity have not been previously evaluated in young mice with a developing heart.
Importantly our experiments began at 4 weeks of age with tumor cell injection. At 1 week post establishment of tumor xenografts, exercise and Doxo commenced and continued in tumor-bearing nude mice (TB-NM) and non-tumorbearing immune competent (NTB-IC) through 7 weeks of age. This time period corresponds with the established timeline of mouse heart development that continues until ∼9 to 10 weeks of age. For example, Piquereau et al 29 studied postnatal mouse heart growth and found that heart mass roughly doubles in size between 3 and 9 weeks of age, a time period that corresponds with the time period assessed in our studies.
In addition, the presence of tumor and the role of the immune system in response to Doxo have not previously been investigated in young mice. Here, we demonstrate the cardioprotective potential of aerobic exercise in clinically relevant pediatric murine models of Doxo-induced cardiotoxicity with and without tumor burden and with and without a functional immune system, when exercise is used during the time frame of Doxo exposure.
MATERIALS AND METHODS

Animals
Animal experiments using NTB-IC mice were performed at Greehey Children's Cancer Research Institute (GCCRI). Experiments with TB-NM were performed at MD Anderson Cancer Center (MDACC). All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) at the institution where they were performed (GCCRI or MDACC).
NTB-IC
C57Bl/6J mice, at 4 weeks of age, were purchased from Jackson Labs. Mice were randomly assigned into 4 groups, with a total of 32 mice (n = 8): sedentary control mice that received drug delivery vehicle (control), sedentary mice that received Doxo, exercised mice that received drug delivery vehicle (Exer), and exercised mice that received Doxo (Doxo +Exer).
TB-NM
Athymic Swiss nude male mice were purchased from MDACC's institutional animal resource. When animals were 4 weeks of age, all mice received subcutaneous injections of 5×10 6 A673 the Ewing sarcoma cells (American Type Culture Collection) in 200 �L PBS. Seven days later, mice were randomly assigned to 1 of 4 groups (32 mice, n = 8 per group): sedentary control mice that received drug delivery vehicle (control), sedentary mice that received Doxo, exercised mice that received drug delivery vehicle (Exer), and exercised mice that received Doxo (Doxo+Exer) using the same treatment schema as for NTB-IC.
Exercise and Doxo Treatment
Treadmill Exercise Protocol
For both protocols, mice were exercised 5 days a week, giving them 2 consecutive off-days for a total of 2 weeks (10 total days of exercise). For TB-NM, exercise was begun 7 days after tumor cell injection, when palpable tumors were present.
Exercise for both TB-NM and NTB-IC mice was administered with a standardized treadmill protocol, which consisted of 45 minutes of constant walking at a rate of 12 m/min at 0% slope with 2 minutes of ramp up from 0 m/ min and 2 minutes of cool down to 0 m/min at the beginning and end of the protocol. Once exercise was concluded, mice were immediately placed back in their cages and allowed to eat and drink freely.
Doxo Treatment
Mice received intraperitoneal injections of 2.5 mg/kg Doxo, twice a week for 2 weeks. Doxo was given on day 3, 5, 10, and 12 after exercise was begun (days 10, 15, 17, 19 after tumor cell inoculation). For graphical representation, please see Figure 1A .
Selection of Doxo Dosing and Equivalence to Humans
The Doxo dosing regimen selected for this study is roughly equivalent to that used in pediatric oncology patients. Nair and Jacob 30 describe a method to easily to convert animal dosing (in mg/kg) to human equivalents (in mg/kg) by dividing the mouse dose (in mg/kg) by 12.3. Therefore, for our model, 4 doses over 2 weeks at 2.5 mg/kg/dose equals a human equivalent dose of 0.813 mg/kg; 10 mg/kg divided by 12.3. From CDC growth charts, we then calculated the surface area for an average 5-year old-male based on 50th percentile for height and weight as follows:
Weight (18 kg Exercise Delivered After Completion of Doxo Exposure (Fig. S1 , Supplemental Digital Content 1, http://links. lww.com/JPHO/A239) Juvenile NTB-IC mice were given a cumulative dose of 25 mg/kg Doxo over 5 weeks, then were divided into groups that performed 8 weeks of exercise (3 d per week using the parameters noted above) or unexercised mice (control). Animals were not pretrained. This was an intentional choice because pretraining animals (before tumor inoculation or Doxo exposure) may cause changes to cardiac fitness that would skew our results. The average pediatric patient in the United States does not meet national guidelines for weekly physical activity, meaning that the patient population that we are trying to model is not pretrained before a cancer diagnosis.
Therefore, mice that are not pretrained make the most appropriate model to study the impact of exercise during Doxo therapy. Because we used a moderate intensity exercise regimen (12 m/min, equivalent to~65% VO 2 max for mice,~brisk walk for humans) and not a high intensity or exhaustive regimen, pretraining was not needed. We did, however, allow animals to acclimate to the treadmill each session by beginning the treadmill at a low speed and slowly increasing to the exercise speed that was used for each 45 minute session.
Echocardiography
Echocardiography was performed before the first bout of exercise in all mice, and again on the final day of the experiment before euthanasia (day 18 after tumor cell inoculation; day 12 after the first day of exercise for all mice).
NTB-IC Mice (GCCRI)
Echocardiography was performed with the Vevo 2100 system (Visualsonics Inc., Toronto, Canada) with a MS400 linear array transducer (30 MHz). The device's transducer was positioned perpendicularly with a stand. Settings for the instrument are described in Table 1 . Frame rate for both B-mode and M-mode was set to > 200 frames per minute. B-mode long axis parasternal images were recorded when optimal views of the aorta, papillary muscle, and endocardium were visible. M-mode short axis images were recorded at the level of the papillary muscles and the left ventricular (LV) muscles was bisected to obtain the optimal M-Mode selection. At least 3 B-mode and M-mode images were captured for each mouse. All images were saved to a local computer and analyzed offline by a technician who was blinded to the animal's age and group. Conventional echocardiographic measurements of the LV included ejection fraction (EF), fractional shortening (FS), end-diastolic dimension, end-systolic dimension, anterior and posterior wall thickness, and mass. For long axis B-mode measurements, the endocardium was traced semiautomatically beginning from the mitral valve and excluding the papillary muscle. EF and FS were calculated by software using standard computational methods.
TB-NM (MDACC)
Cardiac function was measured in anaesthetized mice using transthoracic echocardiography (Vevo 770 echocardiography with a 30 MHz linear signal transducer and 707B probe; VisualSonics, Toronto, CA). The heart was imaged when optimal views of the aorta, papillary muscle, and endocardium were visible in the 2-dimensional mode (B-mode) in the parasternal long axis view. M-mode short axis images were recorded at the level of the papillary muscles and the LV was bisected to obtain the optimal M-Mode selection. The measurements of intraventricular septal thickness, left ventricular posterior wall thickness, and left ventricular internal diameters were made in systole and diastole. The endocardium was traced manually beginning from the mitral valve and excluding the papillary muscle. LV percent FS, EF, chamber volume, and mass were calculated by Vevo 770 software.
Necropsy and Tissue Collection
Within 4 hours after the final bout of exercise and Doxo injection, animals were euthanized by CO 2 and cervical dislocation. The intraperitoneal cavity was exposed and inspected visually before the heart and the tibia were removed. Excess blood was squeezed from the heart before obtaining wet whole heart weight (mg), and tibia was thoroughly cleaned before obtaining tibia length (mm). Heart was then sectioned for histologic evaluation, and 1 piece was snap frozen for future use.
Histology and Immunohistochemistry
One portion of each heart was fixed in 4% PFA at 4 degrees overnight before being embedded in paraffin and sectioned for immunohistochemical analysis. Hematoxylin and eosin staining was performed by the MDACC core facility, and sections were analyzed for cardiomyocyte size (diameter of 100 cells per heart were averaged to obtain 1 value). To evaluate heart vasculature, slides were rehydrated 
Quantitation of Doxo in Myocardial Tissue
TB-NM performed 10 days of exercise as described above but received no Doxo during these 2 weeks. Mice were injected with 10 mg/kg Doxo via tail vein 72 hours after the last exercise session. Twenty minutes later, mice were euthanized and hearts were immediately harvested. A roughly 40 mg portion was collected, weighed, and homogenized in acid isopropanol/Triton-X. Doxo fluorescence was read using a spectrophotometer (OD488) and compared with a standard curve, then normalized against the weight of heart tissue input and the background reading of a heart from a mouse that received no Doxo.
Statistical Analyses
Statistical differences were evaluated using GraphPad Prism 6 software and 2-way analysis of variance or unpaired Student's t test. For each experimental condition, cardiac functional outcomes were compared between control and Doxo-treated animals. To examine the effects of exercise Doxo and Doxo+exercise were compared. For all comparisons, statistical significance was defined as P < 0.05.
RESULTS
Exercise Counteracts Doxo-induced Body Weight and Heart Weight Loss
We first evaluated the use of exercise after Doxo exposure to determine whether exercise could mitigate cardiac toxicity. Juvenile NTB-IC mice were given a cumulative dose of 25 mg/kg Doxo over 5 weeks, then were divided into groups that performed 8 weeks of exercise or unexercised mice (control). Exercise after Doxo exposure afforded no recovery of FS or EF as measured by echocardiogram relative to Doxo-treated animals that did not perform exercise (Fig. S1 , Supplemental Digital Content 1, http://links.lww.com/JPHO/A239). Therefore, we next evaluated whether exercise during the time period of Doxo exposure can be cardioprotective. We used Doxo given twice weekly for 2 weeks to induce cardiac toxicity in 2 parallel mouse models. Nude mice-bearing A673 Ewing's sarcoma tumors (TB-NM) or C57Bl/6 mice without tumors (NTB-IC mice) were treated with 2.5 mg/kg Doxo twice weekly for 2 weeks to induce acute cardiac toxicity. Mice in the Exer or Doxo+Exer group performed treadmill exercise 5 days per week (Fig. 1A) .
Treatment with Doxo caused significant weight loss in nude mice, with or without exercise (Fig. 1B) . In order to model juvenile exposure to Doxo and to evaluate the consequences of exposure during the period of heart growth and development, mice were only 4 weeks old at the beginning of the experiment. Therefore, animals in control and exercise only groups gained weight due to normal growth during the experiment. It is also important to note that tumor shrinkage in response to chemotherapy represented a negligible component of weight loss. In contrast to TB-NM, NTB-IC mice exhibited no significant difference in the amount of weight gained between groups (Fig. 1B) .
There was a significant reduction in heart weight: tibia length in Doxo-treated TB-NM, but not in Doxo-treated NTB-IC mice (Fig. 2A) . To account for the reduction in heart size in nude mice, we examined cardiomyocyte size on histologic sections. There was no difference in cardiomyocyte size (cross-sectional diameter) between hearts from different treatment groups in TB-NM or NTB-IC mice (Fig. 2B and data not shown) . Similarly, there was no obvious difference in the structure of hearts from mice in any group (Fig. 2B and data not shown) .
Doxo-induced Reduction in Cardiac Function is Mitigated by Exercise
Echocardiograms were performed at baseline before exposure to Doxo or Exer, and on the day before euthanasia (Fig. 1A) . FS, EF, and LV posterior wall thickness in systole and diastole were evaluated (Fig. 3A) . In TB-NM and in NTB-IC mice, FS and EF were significantly reduced after Doxo exposure compared with baseline, whereas no change was observed in these functional measures over time in control or exercised animals (Figs. 3B, C) . Importantly, performing exercise in the same time period as Doxo exposure prevented the loss in cardiac function induced by Doxo alone (Figs. 3B, C) . LV posterior wall thickness during systole or diastole were not significantly changed by Doxo or Exer in either model (data not shown).
Exercise Decreases Doxo Accumulation in Cardiac Tissue
The prevention of Doxo-induced cardiotoxicity by exercise suggested that exercise protects the heart cells from Doxo exposure. To explore this possibility, we used A673 TB-NM. Animals were unexercised or performed treadmill running 5 days per week for 2 weeks.
Seventy-two hours after the final day of exercise, mice were given a bolus dose of Doxo before the hearts were harvested and Doxo in the tissue was quantified by spectrophotometry. Hearts from animals in the exercise group had significantly less Doxo than those from control mice (Fig. 4A) . To determine whether the reduced Doxo in the hearts of exercised mice was due to a reduction in vascular density, we performed CD31 staining. However, there was no difference in microvessel density between groups (Fig. 4B) .
DISCUSSION
Doxo is a highly efficacious cytotoxic chemotherapy agent that has been unequivocally associated with acute and chronic cardiac side effects. [1] [2] [3] [4] [5] [6] [7] [8] 11 With respect to the development of late organ toxicities, pediatric patients face potentially worse outcomes in comparison with adult patients treated for cancer, as pediatric patients are still undergoing organ development and remodeling during the time of treatment exposures. Here, we have identified moderate aerobic exercise as an effective intervention in mitigating acute cardiac side effects associated with Doxo exposure in pediatric mice, which implicates exercise as an attractive beneficial adjuvant to chemotherapy in pediatric cancer patients.
Exercise prevented the reduction in FS and EF induced by Doxo in both models. Importantly, Doxo caused a reduction in body weight and in heart: tibia size ratio that was rescued by exercise in TB-NM. Doxo did not cause reductions in body weight or heart weight: tibia length ratio in NTB-IC mice, emphasizing the differences in the 2 models and the importance of utilizing appropriate models for evaluation of Doxo-induced cardiotoxicity. The differential responses between the 2 models suggest that either the American Society of Sports Medicine recommends regular exercise for cancer survivors of all ages. 31 However, no specialized recommendations exist that are specifically designed for pediatric cancer patients and childhood cancer survivors. Research in animal models suggests that exercise promotes various adaptations in the heart and vascular system that make the heart more resilient against various cellular stressors, including oxidative and proteostatic stressors. 32 Notably, each of these has been previously described among the important downstream consequences of Doxo exposure in the heart. Therefore, exercise is a potential intervention that may be a beneficial strategy to reduce treatment-induced cardiac damage in childhood cancer patients.
Current clinical and basic research on how exercise affects the outcome of Doxo exposure have centered on exercise at 3 different time points: before exposure (preconditioning), during treatment, and after treatment (rehabilitation). There is strong animal model evidence that supports the benefit of exercise in pediatric populations and rehabilitation is important in individuals who have developed heart failure. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] Exercise during chemotherapy has been shown to be safe, [33] [34] [35] but the cardioprotective benefits of exercise when delivered during the active treatment phase are still inconclusive. This controversy exists for many reasons, including the difficulty of diagnosing subclinical cardiac dysfunction, persistence of a low grade subclinical cardiac abnormality for several years after anthracycline exposure, and unknown pathologic mechanisms contributing to the development of heart failure in up to 20% of anthracycline-treated cancer patients. 2 As more sensitive clinical measures of cardiac dysfunction are developed and validated, such as strain echocardiography and magnetic resonance imaging, we will begin to develop a better understanding of subclinical cardiac dysfunction and how exercise during anthracycline treatment alters cardiac function throughout a patient's lifetime.
Importantly, most previous studies have not examined how exercise affects Doxo tissue distribution in mice and thus building on the observations presented here could provide novel perspective on how exercise influences Doxo cardiotoxicity and even toxicity in other normal tissue.
Future studies in mice need to focus on fully understanding the pharmacokinetics of Doxo during exercise, as well as how acute Doxo accumulation in the heart can modify the development of cardiac dysfunction throughout the lifespan. Moreover, it is imperative that these evaluations are conducted in relevant preclinical mouse models that account for animal age at exposure and the presence or absence of a tumor and the immune system. Further, a model delivering exercise during Doxo exposure followed by a prolonged latent period before evaluating changes in cardiac function would have the most relevance with respect to pediatric cancer survivors.
In summary, this study performed in pediatric mice suggests that exercise during Doxo exposure may be a
